Literature DB >> 20153883

Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease?

Madeleine Courtney-Brooks1, Paniti Sukumvanich, Sushil Beriwal, Kristin K Zorn, Scott D Richard, Thomas C Krivak.   

Abstract

OBJECTIVE: To determine if the extent of lymphadenectomy as determined by lymph node count from an inguinal-femoral lymph node dissection for vulvar cancer impacts overall survival (OS) and disease-specific survival (DSS) in patients with node-negative disease.
METHODS: Patients with stage I, II and III squamous cell carcinoma of the vulva who underwent primary inguinal-femoral nodal dissection were identified from the Surveillance, Epidemiology and End Results Program between 1988 and 2003. Patients were divided into 2 groups, those with <or=10 nodes and those with >10 nodes removed, and analyzed according to stage. All patients with histologically positive nodes were excluded. Log-rank test was done for univariate analysis. Cox regression method was used for multivariate analysis.
RESULTS: Squamous cell vulvar cancer was identified in 1030 patients. Statistically significant differences were seen on univariate analysis of OS between stage II and III patients with <or=10 and >10 nodes removed. The difference in 5-year DSS survival was statistically significant only for patients with stage III disease. On multivariate analysis age, stage and number of lymph nodes removed were all found to be significant variables affecting OS and DSS.
CONCLUSIONS: The removal of greater than 10 lymph nodes was associated with a significant improvement in DSS in patients with stage III vulvar carcinoma. This improvement in survival may be due to removal of micrometastatic disease in the inguinal lymph nodes. These data suggest that a thorough inguinal-femoral lymph node dissection should be performed in patients with advanced-stage node-negative vulvar carcinoma. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20153883     DOI: 10.1016/j.ygyno.2010.01.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

2.  Risk factors for short- and long-term complications after groin surgery in vulvar cancer.

Authors:  F Hinten; L C G van den Einden; J C M Hendriks; A G J van der Zee; J Bulten; L F A G Massuger; H P van de Nieuwenhof; J A de Hullu
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

3.  Prognosis of vulval cancer with lymph node status and size of primary lesion: A survival study.

Authors:  Pankaj Deka; Debabrata Barmon; Sushrata Shribastava; Amal Chandra Kataki; J D Sharma; M Bhattacharyya
Journal:  J Midlife Health       Date:  2014-01

4.  Four-decade trends in lymph node status of patients with vulvar squamous cell carcinoma in northern Italy.

Authors:  Mario Preti; Lauro Bucchi; Leonardo Micheletti; Silvana Privitera; Monica Corazza; Stefano Cosma; Niccolò Gallio; Alessandro Borghi; Federica Bevilacqua; Chiara Benedetto
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

5.  Safety and feasibility of single-incision radical vulvectomy: a novel approach for the treatment of vulvar cancer.

Authors:  Liqing He; Gaowen Chen; Xiaoxuan Li; Youhong Zheng; Mengting Wu; Huiyan Wang; Xiaohong Liu; Wuqi He; Xiaodan Liu; Shaozhuo Huang; Fan Lin; Weixin Liao; Ying Ma; Yifeng Wang
Journal:  Ann Transl Med       Date:  2021-02

6.  Prognostic Value of the Number of Removed Lymph Nodes in Vulvar Squamous Cell Carcinoma Patients With Node-Positive Disease: A Population-Based Study.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Qiong-Hua Chen; Zhen-Yu He; Juan Zhou
Journal:  Front Oncol       Date:  2018-05-30       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.